1zxm › Citations

Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase.

Wei H, Ruthenburg AJ, Bechis SK, Verdine GL
J Biol Chem 280 37041-7 (2005)
Cited: 141 times
EuropePMC logo PMID: 16100112

Abstract

Type IIA DNA topoisomerases play multiple essential roles in the management of higher-order DNA structure, including modulation of topological state, chromosome segregation, and chromatin condensation. These diverse physiologic functions are all accomplished through a common molecular mechanism, wherein the protein catalyzes transient cleavage of a DNA duplex (the G-segment) to yield a double-stranded gap through which another duplex (the T-segment) is passed. The overall process is orchestrated by the opening and closing of molecular "gates" in the topoisomerase structure, which is regulated by ATP binding, hydrolysis, and release of ADP and inorganic phosphate. Here we present two crystal structures of the ATPase domain of human DNA topoisomerase IIalpha in different nucleotide-bound states. Comparison of these structures revealed rigid-body movement of the structural modules within the ATPase domain, suggestive of the motions of a molecular gate.

Reviews - 1zxm mentioned but not cited (5)

  1. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. Auti PS, George G, Paul AT. RSC Adv 10 41353-41392 (2020)
  2. The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance. Lotz C, Lamour V. Cancer Drug Resist 3 149-160 (2020)
  3. A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents. Okoro CO, Fatoki TH. Int J Mol Sci 24 2532 (2023)
  4. Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90. Jun KY, Kwon Y. Biomol Ther (Seoul) 24 453-468 (2016)
  5. Recent advances in the area of plant-based anti-cancer drug discovery using computational approaches. Das AP, Agarwal SM. Mol Divers (2023)

Articles - 1zxm mentioned but not cited (73)

  1. Predicting new indications for approved drugs using a proteochemometric method. Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, Madhavan S, Uren A, Brown ML, Byers SW. J Med Chem 55 6832-6848 (2012)
  2. 3D-QSAR studies on Maslinic acid analogs for Anticancer activity against Breast Cancer cell line MCF-7. Alam S, Khan F. Sci Rep 7 6019 (2017)
  3. Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα. Lin RK, Zhou N, Lyu YL, Tsai YC, Lu CH, Kerrigan J, Chen YT, Guan Z, Hsieh TS, Liu LF. J Biol Chem 286 33591-33600 (2011)
  4. Ginkgo biloba leaf extract induces DNA damage by inhibiting topoisomerase II activity in human hepatic cells. Zhang Z, Chen S, Mei H, Xuan J, Guo X, Couch L, Dobrovolsky VN, Guo L, Mei N. Sci Rep 5 14633 (2015)
  5. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Hasinoff BB, Wu X, Nitiss JL, Kanagasabai R, Yalowich JC. Biochem Pharmacol 84 1617-1626 (2012)
  6. QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase IIα. Alam S, Khan F. Drug Des Devel Ther 8 183-195 (2014)
  7. Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II. Xu B, Wang L, González-Molleda L, Wang Y, Xu J, Yuan Y. Antimicrob Agents Chemother 58 563-573 (2014)
  8. Structural basis for allosteric regulation of Human Topoisomerase IIα. Vanden Broeck A, Lotz C, Drillien R, Haas L, Bedez C, Lamour V. Nat Commun 12 2962 (2021)
  9. Post-translational modifications in DNA topoisomerase 2α highlight the role of a eukaryote-specific residue in the ATPase domain. Bedez C, Lotz C, Batisse C, Broeck AV, Stote RH, Howard E, Pradeau-Aubreton K, Ruff M, Lamour V. Sci Rep 8 9272 (2018)
  10. Structure of the N-terminal Gyrase B fragment in complex with ADP⋅Pi reveals rigid-body motion induced by ATP hydrolysis. Stanger FV, Dehio C, Schirmer T. PLoS One 9 e107289 (2014)
  11. Emodin regulates neutrophil phenotypes to prevent hypercoagulation and lung carcinogenesis. Li Z, Lin Y, Zhang S, Zhou L, Yan G, Wang Y, Zhang M, Wang M, Lin H, Tong Q, Duan Y, Du G. J Transl Med 17 90 (2019)
  12. Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents. Alam R, Wahi D, Singh R, Sinha D, Tandon V, Grover A, Rahisuddin. Bioorg Chem 69 77-90 (2016)
  13. Systematic analyses on the potential immune and anti-inflammatory mechanisms of Shufeng Jiedu Capsule against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-caused pneumonia. Tao Z, Zhang L, Friedemann T, Yang G, Li J, Wen Y, Wang J, Shen A. J Funct Foods 75 104243 (2020)
  14. Heteroleptic Copper(I) Complexes of "Scorpionate" Bis-pyrazolyl Carboxylate Ligand with Auxiliary Phosphine as Potential Anticancer Agents: An Insight into Cytotoxic Mode. Khan RA, Usman M, Dhivya R, Balaji P, Alsalme A, AlLohedan H, Arjmand F, AlFarhan K, Akbarsha MA, Marchetti F, Pettinari C, Tabassum S. Sci Rep 7 45229 (2017)
  15. LC-MS/MS Phytochemical Profiling, Antioxidant Activity, and Cytotoxicity of the Ethanolic Extract of Atriplex halimus L. against Breast Cancer Cell Lines: Computational Studies and Experimental Validation. Elbouzidi A, Ouassou H, Aherkou M, Kharchoufa L, Meskali N, Baraich A, Mechchate H, Bouhrim M, Idir A, Hano C, Zrouri H, Addi M. Pharmaceuticals (Basel) 15 1156 (2022)
  16. Bioinformatics Screening of Potential Biomarkers from mRNA Expression Profiles to Discover Drug Targets and Agents for Cervical Cancer. Reza MS, Harun-Or-Roshid M, Islam MA, Hossen MA, Hossain MT, Feng S, Xi W, Mollah MNH, Wei Y. Int J Mol Sci 23 3968 (2022)
  17. Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies. Alam MS, Sultana A, Reza MS, Amanullah M, Kabir SR, Mollah MNH. PLoS One 17 e0268967 (2022)
  18. Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets. Gurung AB, Ali MA, Lee J, Farah MA, Al-Anazi KM. PLoS One 16 e0254035 (2021)
  19. Neoamphimedine circumvents metnase-enhanced DNA topoisomerase IIα activity through ATP-competitive inhibition. Ponder J, Yoo BH, Abraham AD, Li Q, Ashley AK, Amerin CL, Zhou Q, Reid BG, Reigan P, Hromas R, Nickoloff JA, LaBarbera DV. Mar Drugs 9 2397-2408 (2011)
  20. Substituted 4,5'-Bithiazoles as Catalytic Inhibitors of Human DNA Topoisomerase IIα. Bergant Loboda K, Janežič M, Štampar M, Žegura B, Filipič M, Perdih A. J Chem Inf Model 60 3662-3678 (2020)
  21. Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II. Xu H, Chen Q, Wang H, Xu P, Yuan R, Li X, Bai L, Xue M. J Exp Clin Cancer Res 35 178 (2016)
  22. Pyrazoline analogs as potential anticancer agents and their apoptosis, molecular docking, MD simulation, DNA binding and antioxidant studies. Rana M, Arif R, Khan FI, Maurya V, Singh R, Faizan MI, Yasmeen S, Dar SH, Alam R, Sahu A, Ahmad T, Rahisuddin. Bioorg Chem 108 104665 (2021)
  23. An improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIα and potent anticancer agent. Li L, Abraham AD, Zhou Q, Ali H, O'Brien JV, Hamill BD, Arcaroli JJ, Messersmith WA, LaBarbera DV. Mar Drugs 12 4833-4850 (2014)
  24. Characterization of a novel anti-cancer compound for astrocytomas. Lee SY, Slagle-Webb B, Rizk E, Patel A, Miller PA, Sung SS, Connor JR. PLoS One 9 e108166 (2014)
  25. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, Messersmith WA, LaBarbera DV. J Med Chem 62 10182-10203 (2019)
  26. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition, in vitro and in silico studies. Othman DIA, Hamdi A, Tawfik SS, Elgazar AA, Mostafa AS. J Enzyme Inhib Med Chem 38 2166037 (2023)
  27. In Silico Investigation of the Anti-Tumor Mechanisms of Epigallocatechin-3-Gallate. Wang W, Xiong X, Li X, Zhang Q, Yang W, Du L. Molecules 24 E1445 (2019)
  28. Cytotoxic effect and molecular docking of 4-ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-thiosemicarbazide--a novel topoisomerase II inhibitor. Siwek A, Stączek P, Wujec M, Bielawski K, Bielawska A, Paneth P. J Mol Model 19 1319-1324 (2013)
  29. Dynophore-Based Approach in Virtual Screening: A Case of Human DNA Topoisomerase IIα. Janežič M, Valjavec K, Loboda KB, Herlah B, Ogris I, Kozorog M, Podobnik M, Grdadolnik SG, Wolber G, Perdih A. Int J Mol Sci 22 13474 (2021)
  30. Interspecies Anticancer and Antimicrobial Activities of Genus Solanum and Estimation of Rutin by Validated UPLC-PDA Method. Alajmi MF, Alam P, Rehman MT, Husain FM, Khan AA, Siddiqui NA, Hussain A, Kalam MA, Parvez MK. Evid Based Complement Alternat Med 2018 6040815 (2018)
  31. Computational screening of chalcones acting against topoisomerase IIα and their cytotoxicity towards cancer cell lines. Sangpheak K, Mueller M, Darai N, Wolschann P, Suwattanasophon C, Ruga R, Chavasiri W, Seetaha S, Choowongkomon K, Kungwan N, Rungnim C, Rungrotmongkol T. J Enzyme Inhib Med Chem 34 134-143 (2019)
  32. Design, Synthesis and Anti-Tumor Activity of Novel Benzimidazole-Chalcone Hybrids as Non-Intercalative Topoisomerase II Catalytic Inhibitors. Zhou W, Zhang W, Peng Y, Jiang ZH, Zhang L, Du Z. Molecules 25 E3180 (2020)
  33. Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors. Li P, Zhang W, Jiang H, Li Y, Dong C, Chen H, Zhang K, Du Z. Medchemcomm 9 1194-1205 (2018)
  34. Pro-Apoptotic Antitumoral Effect of Novel Acridine-Core Naphthoquinone Compounds against Oral Squamous Cell Carcinoma. Zorzanelli BC, Ouverney G, Pauli FP, da Fonseca ACC, de Almeida ECP, de Carvalho DG, Possik PA, Rabelo VW, Abreu PA, Pontes B, Ferreira VF, Forezi LDSM, da Silva FC, Robbs BK. Molecules 27 5148 (2022)
  35. Probing conformational changes in human DNA topoisomerase IIα by pulsed alkylation mass spectrometry. Chen YT, Collins TR, Guan Z, Chen VB, Hsieh TS. J Biol Chem 287 25660-25668 (2012)
  36. Relating the shape of protein binding sites to binding affinity profiles: is there an association? Simon Z, Vigh-Smeller M, Peragovics A, Csukly G, Zahoránszky-Kohalmi G, Rauscher AA, Jelinek B, Hári P, Bitter I, Málnási-Csizmadia A, Czobor P. BMC Struct Biol 10 32 (2010)
  37. Synthesis, molecular docking, ctDNA interaction, DFT calculation and evaluation of antiproliferative and anti-Toxoplasma gondii activities of 2,4-diaminotriazine-thiazole derivatives. Łączkowski KZ, Anusiak J, Świtalska M, Dzitko K, Cytarska J, Baranowska-Łączkowska A, Plech T, Paneth A, Wietrzyk J, Białczyk J. Med Chem Res 27 1131-1148 (2018)
  38. Thiazole-Chalcone Hybrids as Prospective Antitubercular and Antiproliferative Agents: Design, Synthesis, Biological, Molecular Docking Studies and In Silico ADME Evaluation. Kasetti AB, Singhvi I, Nagasuri R, Bhandare RR, Shaik AB. Molecules 26 2847 (2021)
  39. Catalytic Mechanism of ATP Hydrolysis in the ATPase Domain of Human DNA Topoisomerase IIα. Ogrizek M, Janežič M, Valjavec K, Perdih A. J Chem Inf Model 62 3896-3909 (2022)
  40. Chemoselective Synthesis of Mannich Adducts from 1,4-Naphthoquinones and Profile as Autophagic Inducers in Oral Squamous Cell Carcinoma. Borges AA, de Souza MP, da Fonseca ACC, Wermelinger GF, Ribeiro RCB, Amaral AAP, de Carvalho CJC, Abreu LS, de Queiroz LN, de Almeida ECP, Rabelo VW, Abreu PA, Pontes B, Ferreira VF, da Silva FC, Forezi LDSM, Robbs BK. Molecules 28 309 (2022)
  41. Solvent-free synthesis, DNA-topoisomerase II activity and molecular docking study of new asymmetrically N,N'-substituted ureas. Esteves-Souza A, Rodrigues-Santos CE, Del Cistia Cde N, Silva DR, Sant'anna CM, Echevarria A. Molecules 17 12882-12894 (2012)
  42. Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIα inhibiting anticancer agent. Murugavel S, Ravikumar C, Jaabil G, Alagusundaram P. Comput Biol Chem 79 73-82 (2019)
  43. The Antileukemic Effect of Xestoquinone, A Marine-Derived Polycyclic Quinone-Type Metabolite, Is Mediated through ROS-Induced Inhibition of HSP-90. Wang KC, Lu MC, Hsu KC, El-Shazly M, Shih SP, Lien ST, Kuo FW, Yang SC, Chen CL, Yang YSH. Molecules 26 7037 (2021)
  44. Understanding the polypharmacological anticancer effects of Xiao Chai Hu Tang via a computational pharmacological model. Zheng CS, Wu YS, Bao HJ, Xu XJ, Chen XQ, Ye HZ, Wu GW, Xu HF, Li XH, Chen JS, Liu XX. Exp Ther Med 7 1777-1783 (2014)
  45. 3,6-Disubstituted 1,2,4-Triazolo[3,4-b]Thiadiazoles with Anticancer Activity Targeting Topoisomerase II Alpha. Sagredou S, Dalezis P, Nikoleousakos N, Nikolaou M, Voura M, Almpanakis K, Panayiotidis MI, Sarli V, Trafalis DT. Onco Targets Ther 13 7369-7386 (2020)
  46. A comprehensive structural analysis of the ATPase domain of human DNA topoisomerase II beta bound to AMPPNP, ADP, and the bisdioxopiperazine, ICRF193. Ling EM, Baslé A, Cowell IG, van den Berg B, Blower TR, Austin CA. Structure 30 1129-1145.e3 (2022)
  47. Bioinformatics and network-based screening and discovery of potential molecular targets and small molecular drugs for breast cancer. Alam MS, Sultana A, Sun H, Wu J, Guo F, Li Q, Ren H, Hao Z, Zhang Y, Wang G. Front Pharmacol 13 942126 (2022)
  48. Bioinformatics screening of colorectal-cancer causing molecular signatures through gene expression profiles to discover therapeutic targets and candidate agents. Horaira MA, Islam MA, Kibria MK, Alam MJ, Kabir SR, Mollah MNH. BMC Med Genomics 16 64 (2023)
  49. Evaluation of Synthetic 2,4-Disubstituted-benzo[g]quinoxaline Derivatives as Potential Anticancer Agents. Zaki I, Abu El-Ata SA, Fayad E, Abu Ali OA, Abu Almaaty AH, Saad AS. Pharmaceuticals (Basel) 14 853 (2021)
  50. Identification of potent catalytic inhibitors of human DNA topoisomerase II by structure-based virtual screening. Dong G, Wu Y, Sun Y, Liu N, Wu S, Zhang W, Sheng C. Medchemcomm 9 1142-1146 (2018)
  51. Synthesis, biological evaluation and virtual screening of some acridone derivatives as potential anticancer agents. Oyedele AS, Bogan DN, Okoro CO. Bioorg Med Chem 28 115426 (2020)
  52. The influence of variations of furanosesquiterpenoids content of commercial samples of myrrh on their biological properties. Alqahtani AS, Noman OM, Rehman MT, Siddiqui NA, Alajmi MF, Nasr FA, Shahat AA, Alam P. Saudi Pharm J 27 981-989 (2019)
  53. Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer. Alam MS, Sultana A, Wang G, Haque Mollah MN. Front Mol Biosci 9 1049741 (2022)
  54. Molecular docking elucidates the plausible mechanisms underlying the anticancer properties of acetyldigitoxigenin from Adenium obesum. Gurung AB, Ali MA, Lee J, Al-Hemaid F, Farah MA, Al-Anazi KM. Saudi J Biol Sci 27 1907-1911 (2020)
  55. Novel topoisomerase II/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2',3':4,5]thiazolo[3,2-a]pyrimidine hybrids as potential anticancer agents with apoptosis inducing activity. Mourad MAE, Abo Elmaaty A, Zaki I, Mourad AAE, Hofni A, Khodir AE, Aboubakr EM, Elkamhawy A, Roh EJ, Al-Karmalawy AA. J Enzyme Inhib Med Chem 38 2205043 (2023)
  56. Prostaglandins Isolated from the Octocoral Plexaura homomalla: In Silico and In Vitro Studies Against Different Enzymes of Cancer. Hurtado DX, Castellanos FA, Coy-Barrera E, Tello E. Mar Drugs 18 E141 (2020)
  57. Synthesis and Biological Evaluation of 4β-N-Acetylamino Substituted Podophyllotoxin Derivatives as Novel Anticancer Agents. Wei J, Chen J, Ju P, Ma L, Chen L, Ma W, Zheng T, Yang G, Wang YX. Front Chem 7 253 (2019)
  58. Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors. Han X, Zhong Y, Zhou G, Qi H, Li S, Ding Q, Liu Z, Song Y, Qiao X. Bioorg Med Chem 25 3116-3126 (2017)
  59. Synthesis and photobiological applications of naphthalimide-benzothiazole conjugates: cytotoxicity and topoisomerase IIα inhibition. Singh I, Luxami V, Choudhury D, Paul K. RSC Adv 12 483-497 (2021)
  60. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  61. Antiproliferative and Enzyme Docking Analysis of Engleromycin from Engleromyces goetzei. Zhang Y, Chen G, Ma H, Guo M. Molecules 24 E166 (2019)
  62. Facile Synthesis of Some Coumarin Derivatives and Their Cytotoxicity through VEGFR2 and Topoisomerase II Inhibition. Gomaa MS, Ali IAI, El Enany G, El Ashry ESH, El Rayes SM, Fathalla W, Ahmed AHA, Abubshait SA, Abubshait HA, Nafie MS. Molecules 27 8279 (2022)
  63. Metadata analysis to explore hub of the hub-genes highlighting their functions, pathways and regulators for cervical cancer diagnosis and therapies. Reza MS, Hossen MA, Harun-Or-Roshid M, Siddika MA, Kabir MH, Mollah MNH. Discov Oncol 13 79 (2022)
  64. Molecular docking analysis of α-Topoisomerase II with δ-Carboline derivatives as potential anticancer agents. Ayyamperumal S, Dj D, Tallapaneni V, Mohan S, S B, Selvaraj J, Joghee NM, Mjn C. Bioinformation 17 249-265 (2021)
  65. Study of Genotoxicity, Activities on Caspase 8 and on the Stabilization of the Topoisomerase Complex of Isoeleutherin and Analogues. Albuquerque KCO, Galucio NCDR, Ferreira GG, Quaresma ACS, Vale VV, Bahia MO, Burbano RMR, Molfetta FA, Percario S, Dolabela MF. Molecules 28 1630 (2023)
  66. In-Silico Prediction of Novel Fused Quinazoline Based Topoisomerase Inhibitors as Anticancer Agents. Kumawat MK, Kaur R, Kumar K. Med Chem 19 431-444 (2023)
  67. Cytotoxicity and Genotoxicity Evaluation of Zanthoxylum rhoifolium Lam and In Silico Studies of Its Alkaloids. Azonsivo R, Albuquerque KCO, Castro ALG, Correa-Barbosa J, Souza HJR, Almada-Vilhena AO, Ferreira GG, Souza AA, Marinho AMDR, Percario S, Nagamachi CY, Pieczarka JC, Dolabela MF. Molecules 28 5336 (2023)
  68. Deep learning-assisted high-content screening identifies isoliquiritigenin as an inhibitor of DNA double-strand breaks for preventing doxorubicin-induced cardiotoxicity. Chen X, Liu C, Zhao H, Zhong Y, Xu Y, Wang Y. Biol Direct 18 63 (2023)
  69. Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy. Pan X, Mao TY, Mai YW, Liang CC, Huang WH, Rao Y, Huang ZS, Huang SL. Molecules 27 5561 (2022)
  70. Effects of In Vitro Digestion of Polyphenols from Coffee on Binding Parameters to Human Topoisomerase II α. Grzelczyk J, Pérez-Sánchez H, Carmena-Bargueño M, Oracz J, Budryn G. Molecules 28 5996 (2023)
  71. Phenotypic Discovery of Thiocarbohydrazone with Anticancer Properties and Catalytic Inhibition of Human DNA Topoisomerase IIα. Cvijetić IN, Herlah B, Marinković A, Perdih A, Bjelogrlić SK. Pharmaceuticals (Basel) 16 341 (2023)
  72. The binding proximity of methyl β-lilacinobioside isolated from Caralluma retrospiciens with topoisomerase II attributes apoptosis in breast cancer cell line. Alallah MI, Alhemaid F, Bai F, Mothana RA, Elshikh MS, Abul Farah M, Ali MA, Lee J, Al-Anazi KM. Saudi J Biol Sci 25 1826-1833 (2018)
  73. YM155 Induces DNA Damage and Cell Death in Anaplastic Thyroid Cancer Cells by Inhibiting DNA Topoisomerase IIα at the ATP-Binding Site. Mackay RP, Weinberger PM, Copland JA, Mahdavian E, Xu Q. Mol Cancer Ther 21 925-935 (2022)


Reviews citing this publication (15)

  1. DNA topoisomerase II and its growing repertoire of biological functions. Nitiss JL. Nat Rev Cancer 9 327-337 (2009)
  2. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Schoeffler AJ, Berger JM. Q Rev Biophys 41 41-101 (2008)
  3. DNA topoisomerase II, genotoxicity, and cancer. McClendon AK, Osheroff N. Mutat Res 623 83-97 (2007)
  4. Recent developments in topoisomerase-targeted cancer chemotherapy. Hevener K, Verstak TA, Lutat KE, Riggsbee DL, Mooney JW. Acta Pharm Sin B 8 844-861 (2018)
  5. TOP2B: The First Thirty Years. Austin CA, Lee KC, Swan RL, Khazeem MM, Manville CM, Cridland P, Treumann A, Porter A, Morris NJ, Cowell IG. Int J Mol Sci 19 E2765 (2018)
  6. The ancestral role of ATP hydrolysis in type II topoisomerases: prevention of DNA double-strand breaks. Bates AD, Berger JM, Maxwell A. Nucleic Acids Res 39 6327-6339 (2011)
  7. Structural frameworks for considering microbial protein- and nucleic acid-dependent motor ATPases. Thomsen ND, Berger JM. Mol Microbiol 69 1071-1090 (2008)
  8. DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery. García-Estrada C, Prada CF, Fernández-Rubio C, Rojo-Vázquez F, Balaña-Fouce R. Proc Biol Sci 277 1777-1787 (2010)
  9. DNA topoisomerase-targeting chemotherapeutics: what's new? Cuya SM, Bjornsti MA, van Waardenburg RCAM. Cancer Chemother Pharmacol 80 1-14 (2017)
  10. The use of divalent metal ions by type II topoisomerases. Deweese JE, Osheroff N. Metallomics 2 450-459 (2010)
  11. Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery. Balaña-Fouce R, Alvarez-Velilla R, Fernández-Prada C, García-Estrada C, Reguera RM. Int J Parasitol Drugs Drug Resist 4 326-337 (2014)
  12. The role of ATP-dependent machines in regulating genome topology. Hauk G, Berger JM. Curr Opin Struct Biol 36 85-96 (2016)
  13. Analysis of the eukaryotic topoisomerase II DNA gate: a single-molecule FRET and structural perspective. Collins TR, Hammes GG, Hsieh TS. Nucleic Acids Res 37 712-720 (2009)
  14. A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone. Bisacchi GS, Hale MR. Curr Med Chem 23 520-577 (2016)
  15. Targeting DNA Topoisomerase II in Antifungal Chemotherapy. Kondaka K, Gabriel I. Molecules 27 7768 (2022)

Articles citing this publication (48)

  1. Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity. Schmidt BH, Osheroff N, Berger JM. Nat Struct Mol Biol 19 1147-1154 (2012)
  2. Holoenzyme assembly and ATP-mediated conformational dynamics of topoisomerase VI. Corbett KD, Benedetti P, Berger JM. Nat Struct Mol Biol 14 611-619 (2007)
  3. A domain insertion in Escherichia coli GyrB adopts a novel fold that plays a critical role in gyrase function. Schoeffler AJ, May AP, Berger JM. Nucleic Acids Res 38 7830-7844 (2010)
  4. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II. Li Y, Luan Y, Qi X, Li M, Gong L, Xue X, Wu X, Wu Y, Chen M, Xing G, Yao J, Ren J. Toxicol Sci 118 435-443 (2010)
  5. Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. Chène P, Rudloff J, Schoepfer J, Furet P, Meier P, Qian Z, Schlaeppi JM, Schmitz R, Radimerski T. BMC Chem Biol 9 1 (2009)
  6. PTEN stabilizes TOP2A and regulates the DNA decatenation. Kang X, Song C, Du X, Zhang C, Liu Y, Liang L, He J, Lamb K, Shen WH, Yin Y. Sci Rep 5 17873 (2015)
  7. Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate. Chen SF, Huang NL, Lin JH, Wu CC, Wang YR, Yu YJ, Gilson MK, Chan NL. Nat Commun 9 3085 (2018)
  8. Mitochondrial Hsp90 is a ligand-activated molecular chaperone coupling ATP binding to dimer closure through a coiled-coil intermediate. Sung N, Lee J, Kim JH, Chang C, Joachimiak A, Lee S, Tsai FT. Proc Natl Acad Sci U S A 113 2952-2957 (2016)
  9. Resveratrol: A novel type of topoisomerase II inhibitor. Lee JH, Wendorff TJ, Berger JM. J Biol Chem 292 21011-21022 (2017)
  10. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Hu CX, Zuo ZL, Xiong B, Ma JG, Geng MY, Lin LP, Jiang HL, Ding J. Mol Pharmacol 70 1593-1601 (2006)
  11. Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapy. Williamson EA, Damiani L, Leitao A, Hu C, Hathaway H, Oprea T, Sklar L, Shaheen M, Bauman J, Wang W, Nickoloff JA, Lee SH, Hromas R. Cancer Res 72 6200-6208 (2012)
  12. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma. Dong H, Yang X, Xie J, Xiang L, Li Y, Ou M, Chi T, Liu Z, Yu S, Gao Y, Chen J, Shao J, Jia L. Biochem Pharmacol 93 151-162 (2015)
  13. Anthracyclines as effective anticancer drugs. Nadas J, Sun D. Expert Opin Drug Discov 1 549-568 (2006)
  14. Coupling between ATP binding and DNA cleavage by DNA topoisomerase II: A unifying kinetic and structural mechanism. Mueller-Planitz F, Herschlag D. J Biol Chem 283 17463-17476 (2008)
  15. Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I. Furet P, Schoepfer J, Radimerski T, Chène P. Bioorg Med Chem Lett 19 4014-4017 (2009)
  16. Mechanism of inhibition of the ATPase domain of human topoisomerase IIα by 1,4-benzoquinone, 1,2-naphthoquinone, 1,4-naphthoquinone, and 9,10-phenanthroquinone. Gurbani D, Kukshal V, Laubenthal J, Kumar A, Pandey A, Tripathi S, Arora A, Jain SK, Ramachandran R, Anderson D, Dhawan A. Toxicol Sci 126 372-390 (2012)
  17. Mycobacterium tuberculosis DNA gyrase ATPase domain structures suggest a dissociative mechanism that explains how ATP hydrolysis is coupled to domain motion. Agrawal A, Roué M, Spitzfaden C, Petrella S, Aubry A, Hann M, Bax B, Mayer C. Biochem J 456 263-273 (2013)
  18. Cancer-relevant biochemical targets of cytotoxic Lonchocarpus flavonoids: a molecular docking analysis. Cassidy CE, Setzer WN. J Mol Model 16 311-326 (2010)
  19. Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity. Baviskar AT, Banerjee UC, Gupta M, Singh R, Kumar S, Gupta MK, Kumar S, Raut SK, Khullar M, Singh S, Kumar R. Bioorg Med Chem 21 5782-5793 (2013)
  20. 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site. Pogorelčnik B, Janežič M, Sosič I, Gobec S, Solmajer T, Perdih A. Bioorg Med Chem 23 4218-4229 (2015)
  21. E. coli Gyrase Fails to Negatively Supercoil Diaminopurine-Substituted DNA. Fernández-Sierra M, Shao Q, Fountain C, Finzi L, Dunlap D. J Mol Biol 427 2305-2318 (2015)
  22. Human topoisomerase II-DNA interaction study by using atomic force microscopy. Alonso-Sarduy L, Roduit C, Dietler G, Kasas S. FEBS Lett 585 3139-3145 (2011)
  23. Benzo[b]tryptanthrin inhibits MDR1, topoisomerase activity, and reverses adriamycin resistance in breast cancer cells. Jun KY, Park SE, Liang JL, Jahng Y, Kwon Y. ChemMedChem 10 827-835 (2015)
  24. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II. Zhuo ST, Li CY, Hu MH, Chen SB, Yao PF, Huang SL, Ou TM, Tan JH, An LK, Li D, Gu LQ, Huang ZS. Org Biomol Chem 11 3989-4005 (2013)
  25. Trapping of the transport-segment DNA by the ATPase domains of a type II topoisomerase. Laponogov I, Pan XS, Veselkov DA, Skamrova GB, Umrekar TR, Fisher LM, Sanderson MR. Nat Commun 9 2579 (2018)
  26. Monocyclic 4-amino-6-(phenylamino)-1,3,5-triazines as inhibitors of human DNA topoisomerase IIα. Pogorelčnik B, Brvar M, Zajc I, Filipič M, Solmajer T, Perdih A. Bioorg Med Chem Lett 24 5762-5768 (2014)
  27. mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity. Gilroy KL, Leontiou C, Padget K, Lakey JH, Austin CA. Nucleic Acids Res 34 1597-1607 (2006)
  28. Discovery of mono- and disubstituted 1H-pyrazolo[3,4]pyrimidines and 9H-purines as catalytic inhibitors of human DNA topoisomerase IIα. Pogorelčnik B, Brvar M, Žegura B, Filipič M, Solmajer T, Perdih A. ChemMedChem 10 345-359 (2015)
  29. Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic α-aminophosphonates that act as novel topoisomerase II inhibitors. Ma Y, Wang JG, Wang B, Li ZM. J Mol Model 17 1899-1909 (2011)
  30. Restoration of topoisomerase 2 function by complementation of defective monomers in Drosophila. Hohl AM, Thompson M, Soshnev AA, Wu J, Morris J, Hsieh TS, Wu CT, Geyer PK. Genetics 192 843-856 (2012)
  31. A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents. Blower TR, Bandak A, Lee ASY, Austin CA, Nitiss JL, Berger JM. Nucleic Acids Res 47 8163-8179 (2019)
  32. The HSP90 and DNA topoisomerase VI inhibitor radicicol also inhibits human type II DNA topoisomerase. Gadelle D, Graille M, Forterre P. Biochem Pharmacol 72 1207-1216 (2006)
  33. Design and synthesis of DNA-intercalative naphthalimide-benzothiazole/cinnamide derivatives: cytotoxicity evaluation and topoisomerase-IIα inhibition. Sankara Rao N, Nagesh N, Lakshma Nayak V, Sunkari S, Tokala R, Kiranmai G, Regur P, Shankaraiah N, Kamal A. Medchemcomm 10 72-79 (2019)
  34. Drug-induced conformational population shifts in topoisomerase-DNA ternary complexes. Huang NL, Lin JH. Molecules 19 7415-7428 (2014)
  35. 2-aryl benzimidazole conjugate induced apoptosis in human breast cancer MCF-7 cells through caspase independent pathway. Nayak VL, Nagesh N, Ravikumar A, Bagul C, Vishnuvardhan MVPS, Srinivasulu V, Kamal A. Apoptosis 22 118-134 (2017)
  36. Conjugation with polyamines enhances the antitumor activity of naphthoquinones against human glioblastoma cells. Romão L, do Canto VP, Netz PA, Moura-Neto V, Pinto ÂC, Follmer C. Anticancer Drugs 29 520-529 (2018)
  37. Dynamics of strand passage catalyzed by topoisomerase II. Xie P. Eur Biophys J 39 1251-1259 (2010)
  38. Extensive Bioinformatics Analyses Reveal a Phylogenetically Conserved Winged Helix (WH) Domain (Zτ) of Topoisomerase IIα, Elucidating Its Very High Affinity for Left-Handed Z-DNA and Suggesting Novel Putative Functions. Bartas M, Slychko K, Červeň J, Pečinka P, Arndt-Jovin DJ, Jovin TM. Int J Mol Sci 24 10740 (2023)
  39. Newly discovered chroman-2,4-diones neutralize the in vivo DNA damage induced by alkylation through the inhibition of Topoisomerase IIα: A story behind the molecular modeling approach. Mladenović M, Stanković N, Matić S, Stanić S, Mihailović M, Mihailović V, Katanić J, Boroja T, Vuković N. Biochem Pharmacol 98 243-266 (2015)
  40. Anticancer activity of dihydropyrazolo[1,5-c]quinazolines against rat C6 glioma cells via inhibition of topoisomerase II. Kaur G, Cholia RP, Joshi G, Amrutkar SM, Kalra S, Mantha AK, Banerjee UC, Kumar R. Arch Pharm (Weinheim) 351 e1800023 (2018)
  41. Molecular docking studies of the interaction between propargylic enol ethers and human DNA topoisomerase IIα. Silveira-Dorta G, Sousa IJ, Ríos-Luci C, Martín VS, Fernandes MX, Padrón JM, Padrón JM. Bioorg Med Chem Lett 23 5382-5384 (2013)
  42. SMCHD1's ubiquitin-like domain is required for N-terminal dimerization and chromatin localization. Gurzau AD, Horne CR, Mok YF, Iminitoff M, Willson TA, Young SN, Blewitt ME, Murphy JM. Biochem J 478 2555-2569 (2021)
  43. SMS 2.0: an updated database to study the structural plasticity of short peptide fragments in non-redundant proteins. Ravella D, Kumar MU, Sherlin D, Shankar M, Vaishnavi MK, Sekar K. Genomics Proteomics Bioinformatics 10 44-50 (2012)
  44. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors. Park S, Hong E, Kwak SY, Jun KY, Lee ES, Kwon Y, Na Y. Eur J Med Chem 123 211-225 (2016)
  45. Vibrational spectroscopic studies and molecular docking of 10,10-Dimethylanthrone. Sheena Mary Y, Yamuna TS, Panicker CY, Yathirajan HS, Siddegowda MS, Al-Saadi AA, Van Alsenoy C, War JA. Spectrochim Acta A Mol Biomol Spectrosc 135 652-661 (2015)
  46. Crystal structure of (3E)-5-nitro-3-(2-phenyl-hydrazinyl-idene)-1H-indol-2(3H)-one. Velasques JM, Gervini VC, Bortoluzzi AJ, de Farias RL, de Oliveira AB. Acta Crystallogr E Crystallogr Commun 73 168-172 (2017)
  47. HToPred: A Tool for Human Topoisomerase II Inhibitor Prediction. Tripathi N, Shaikh N, Bharatam PV, Garg P. Mol Inform 38 e1800046 (2019)
  48. Unveiling the interdomain dynamics of type II DNA topoisomerase through all-atom simulations: Implications for understanding its catalytic cycle. Pavlin M, Herlah B, Valjavec K, Perdih A. Comput Struct Biotechnol J 21 3746-3759 (2023)


Quick links